AMEX listing
GAITHERSBURG, Md., Aug 21, 2000 /PRNewswire via COMTEX/ -- Antex Biologics Inc announced today that its common stock will start trading
on The American Stock Exchange (AMEX) shortly under the new symbol ANX. The Company has been notified by the exchange that all
conditions for listing have been met.
"Listing on the AMEX represents a very significant step forward in our company's development. The recognition of Antex's leadership in the
discovery and development of products to prevent and treat infections and related diseases continues to grow," noted Dr. V. M. Esposito, CEO
and Chairman of the Board of Antex. "Antex seeks to develop and market novel preventative and therapeutic products for infants, children,
adolescents and adults., and as a result to enhance shareholder value. We believe the AMEX listing should greatly increase our shareholder
base, provide greater liquidity, and enhance awareness of our efforts among both individual and institutional investors," observed Esposito
Antex Biologics was recently named, for the fourth year in a row, one of the "Deloitte & Touche Maryland Fast50" for 2000, which ranks the
fastest growing technology companies in Maryland. Rankings are based on the percentage of revenue growth over the five-year period of
1995-1999. Companies named from each Regional Fast50 contest are automatically nominated as contestants for the National Fast500
program, which recognizes the fastest growing technology companies throughout the nation. Antex was named in 1997, 1998 and 1999 not
only as a Maryland Fast50 company but also as a National Fast500 company.
Antex develops vaccines and antibiotics to prevent and treat infections and related diseases. Antex has developed three strong platform
technologies, ART(TM), NST(TM), and VEP(TM), and has discovered through its functional genomics and proteomics programs many proteins
for new vaccines and novel antibacterial targets. Antex's VEP(TM) platform technology, which capitalizes on the explosion of genomic
information by integrating NST(TM) with genomic expression profiling, functional genomics and proteomics, has thrust Antex to the forefront of
biotechnology. Antex has adopted a business strategy that includes licensing of specific vaccine products for development by other companies,
as well internal product development and future commercialization.
The strength of Antex's science has received international recognition and is the subject of over 100 issued worldwide patents. These
technologies and discoveries were the keystones for forging strategic alliances with major pharmaceutical companies including Aventis
Pasteur, SmithKline Beecham, and Pfizer, who are responsible for developing and commercializing Antex-licensed vaccines. Another of Antex's
partners is the U.S. Department of Defense, which is providing clinical development funding for the development of a vaccine to prevent
Traveler's Diarrhea.
Antex's current product development program also includes HELIVAX(TM), a vaccine to prevent and eradicate Helicobacter pylori infections,
along with vaccines to prevent infections by Chlamydia trachomatis, a bacteria responsible for sexually transmitted diseases, and Chlamydia
pneumoniae, which causes respiratory infections and has been associated with heart disease and Alzheimer's disease. ACTIVAX(TM) is a
multicomponent vaccine that will be indicated for the prevention of Traveler's Diarrhea. This vaccine is comprised of CAMPYVAX(TM), a vaccine
to prevent Campylobacter infections that is currently in human clinical trials, along with vaccines to prevent disease caused by Shigella and E.
coli bacteria. Also within Antex's pipeline of products are new chemical entities that are being developed as antibiotics for nosocomial (hospital
acquired) infections and other specific bacterial pathogens.
Statements contained herein that are not historical facts regarding the ability to maintain a higher stock price and increase shareholder value
may be forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are subject to a variety of risks and uncertainties that may cause actual results to differ materially from those
expressed in any forward-looking statements made by the Company. Such factors are fully described in the Company's Form 10-KSB filed with
the United States Securities and Exchange Commission, and include, but are not limited to: (i) the Company's ability to fund its future
operations; (ii) the Company's ability to successfully complete product research and development, including preclinical and clinical studies and
commercialization; (iii) the Company's ability to obtain required governmental approvals; (iv) the Company's ability to attract and/or maintain
manufacturing, sales, distribution and marketing partners; and (v) the Company's ability to develop and commercialize its products before its
competitors.
SOURCE Antex Biologics
CONTACT: Stephen Keith, MD, President of Antex Biologics Inc.,
301-590-0129; or Thomas Redington of Redington Inc., 203-222-7399, or
212-926-1733, for Antex Biologics |
